Aflibercept (2.0 mg)
NCRVA-2013-Newton-4-01
Approved small_molecule completed
Quick answer
Aflibercept (2.0 mg) for Macular Edema With Central Retinal Vein Occlusions is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Macular Edema With Central Retinal Vein Occlusions
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed